HALT PROGRESSION OF POLYCYSTIC KIDNEY DISEASE

阻止多囊肾疾病的进展

• 批准号: 7603623
• 负责人: ARLENE B CHAPMAN
• 金额: $ 4.16万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7603623
• 关键词: Antihypertensive Agents; Autosomal Dominant Polycystic Kidney; Blood Pressure; Cessation of life; Combined Modality Therapy; Computer Retrieval of Information on Scientific Projects Database; Creatinine; End stage renal failure; Funding; Grant; Hypertension; Hypotension; Institution; Kidney; Kidney Failure; Polycystic Kidney Diseases; Renal function; Research; Research Personnel; Resources; Serum; Source; Standards of Weights and Measures; Time; United States National Institutes of Health; Upper arm; blood pressure regulation

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study has two arms, the aim in study A is to determine whether ADPKD subjects with preserved renal function (GFR >60 ml/min/1.73m2) and high-normal blood pressure or hypertension, ACE-I/ARB combination therapy and low blood pressure vs ¿-blocker and usual blood pressure reduces the percent increase in kidney volume over time. The aim in study B is to determine whether ADPKD subjects with moderate renal insufficiency (GFR 30-60 ml/min/1.73m2), ACE-I/ARB combination therapy as compared to ACE-I, with additional antihypertensive agents at standard blood pressure control (?130/85 mm Hg), increases the time to doubling of serum creatinine, ESRD or death.

该副本是使用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这是调查员的机构。 这项研究有两个臂，研究A的目的是确定具有保留肾功能的ADPKD受试者（GFR> 60 mL/min/min/1.73m2）和高正常血压或高血压，ACE-I/ARB组合疗法和低血压和低血压VS.-Blocks vs.-Blocks vs.-降低血压是否会增加KIDNEY ADNEY量的百分比。 The aim in study B is to determine whether ADPKD subjects with modern renal insufficiency (GFR 30-60 ml/min/1.73m2), ACE-I/ARB combination therapy as compared to ACE-I, with additional antihypertensive agents at standard blood pressure control (?130/85 mm Hg), increases the time to double of serum creatinine, ESRD or death.